This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosato, R. R. Articles by Grant, S. Search for Related Content PubMed PubMed Citation Articles by Rosato, R. R. Articles by Grant, S.

The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21^{CIP1/WAF1 1}

Departments of Medicine [R. R. R., J. A. A., S. G.], Pharmacology [S. G.], and Biochemistry [S. G.], Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298

Effects of the histone deacetylase (HDAC) inhibitor MS-275 have been examined in human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary acute myelogenous leukemia blasts in relation to differentiation and apoptosis. MS-275 displayed dose-dependent effects in each of the cell lines. When administered at a low concentration (e.g., 1 µM), MS-275 exhibited potent antiproliferative activity, inducing p21^CIP1/WAF1-mediated growth arrest and expression of differentiation markers (CD11b) in U937 cells. These events were accompanied by an increase in hypophosphorylated retinoblastoma protein and down-regulation of cell cycle-related proteins including cylin D1. However, at higher concentrations (e.g., 5 µM), MS-275 potently induced cell death, triggering apoptosis in 70% of cells at 48 h. In contrast to other HDAC inhibitors such as apicidin, the extrinsic, receptor-mediated pathway played a minimal role in MS-275 lethality. However, MS-275 potently induced a very early (e.g., within 2 h) increase in reactive oxygen species (ROS), followed by the loss of mitochondrial membrane potential (_m) and cytosolic release of cytochrome c. These events culminated in activation of the caspase cascade, manifested by poly(ADP-ribose) polymerase, p21^CIP1/WAF1, p27^KIP, Bcl-2, and retinoblastoma protein degradation. MS-275 exposure also resulted in diminished expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. Administration of the free radical scavenger L-N-acetylcysteine blocked MS-275-mediated mitochondrial injury and apoptosis, suggesting a primary role for ROS generation in MS-275-associated lethality. Lastly, U937 cells stably expressing a p21^CIP1/WAF1 antisense construct were significantly more sensitive to MS-275-mediated apoptosis than controls, but they were impaired in their differentiation response. Together, these findings demonstrate that MS-275 exerts dose-dependent effects in human leukemia cells, i.e., p21^CIP1/WAF1-dependent growth arrest and differentiation at low drug concentrations and a marked induction of ROS, mitochondrial damage, caspase activation, and apoptosis at higher concentrations.

This article has been cited by other articles:

				R. R. Rosato, J. A. Almenara, S. C. Maggio, S. Coe, P. Atadja, P. Dent, and S. Grant Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Mol. Cancer Ther., October 1, 2008; 7(10): 3285 - 3297. [Abstract] [Full Text] [PDF]

				Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate Blood, August 1, 2008; 112(3): 793 - 804. [Abstract] [Full Text] [PDF]

				L. Gore, M. L. Rothenberg, C. L. O'Bryant, M. K. Schultz, A. B. Sandler, D. Coffin, C. McCoy, A. Schott, C. Scholz, and S. G. Eckhardt A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas Clin. Cancer Res., July 15, 2008; 14(14): 4517 - 4525. [Abstract] [Full Text] [PDF]

				M. S. Makki, T. Heinzel, and C. Englert TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels Nucleic Acids Res., July 1, 2008; 36(12): 4067 - 4078. [Abstract] [Full Text] [PDF]

				S. Liu, H. Cheng, W. Kwan, J. M. Lubieniecka, and T. O. Nielsen Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models Mol. Cancer Ther., June 1, 2008; 7(6): 1751 - 1761. [Abstract] [Full Text] [PDF]

				C. L. Dalgard, K. R. Van Quill, and J. M. O'Brien Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma Clin. Cancer Res., May 15, 2008; 14(10): 3113 - 3123. [Abstract] [Full Text] [PDF]

				V. R. Fantin and V. M. Richon Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, S. Coe, and S. Grant The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation Cancer Res., October 1, 2007; 67(19): 9490 - 9500. [Abstract] [Full Text] [PDF]

				S. Kummar, M. Gutierrez, E. R. Gardner, E. Donovan, K. Hwang, E. J. Chung, M.-J. Lee, K. Maynard, M. Kalnitskiy, A. Chen, et al. Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies Clin. Cancer Res., September 15, 2007; 13(18): 5411 - 5417. [Abstract] [Full Text] [PDF]

				J. S. Carew, S. T. Nawrocki, C. N. Kahue, H. Zhang, C. Yang, L. Chung, J. A. Houghton, P. Huang, F. J. Giles, and J. L. Cleveland Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance Blood, July 1, 2007; 110(1): 313 - 322. [Abstract] [Full Text] [PDF]

				R. K. Lindemann, A. Newbold, K. F. Whitecross, L. A. Cluse, A. J. Frew, L. Ellis, S. Williams, A. P. Wiegmans, A. E. Dear, C. L. Scott, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma PNAS, May 8, 2007; 104(19): 8071 - 8076. [Abstract] [Full Text] [PDF]

				V. Moneo, B. G. Serelde, J. F.M. Leal, C. Blanco-Aparicio, R. Diaz-Uriarte, M. Aracil, J. C. Tercero, J. Jimeno, and A. Carnero Levels of p27kip1 determine Aplidin sensitivity Mol. Cancer Ther., April 1, 2007; 6(4): 1310 - 1316. [Abstract] [Full Text] [PDF]

				I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood, April 1, 2007; 109(7): 2781 - 2790. [Abstract] [Full Text] [PDF]

				C. Yu, B. B. Friday, J.-P. Lai, A. McCollum, P. Atadja, L. R. Roberts, and A. A. Adjei Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation Clin. Cancer Res., February 15, 2007; 13(4): 1140 - 1148. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, S. S. Kolla, S. C. Maggio, S. Coe, M. S. Gimenez, P. Dent, and S. Grant Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions Mol. Cancer Ther., February 1, 2007; 6(2): 692 - 702. [Abstract] [Full Text] [PDF]

				Y. Kato, B. C. Salumbides, X.-F. Wang, D. Z. Qian, S. Williams, Y. Wei, T. B. Sanni, P. Atadja, and R. Pili Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma Mol. Cancer Ther., January 1, 2007; 6(1): 70 - 81. [Abstract] [Full Text] [PDF]

				Y. Kawai and I. J. Arinze Valproic Acid-Induced Gene Expression through Production of Reactive Oxygen Species. Cancer Res., July 1, 2006; 66(13): 6563 - 6569. [Abstract] [Full Text] [PDF]

				S. Inoue, A. Mai, M. J.S. Dyer, and G. M. Cohen Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Cancer Res., July 1, 2006; 66(13): 6785 - 6792. [Abstract] [Full Text] [PDF]

				C. Foglietti, G. Filocamo, E. Cundari, E. De Rinaldis, A. Lahm, R. Cortese, and C. Steinkuhler Dissecting the Biological Functions of Drosophila Histone Deacetylases by RNA Interference and Transcriptional Profiling J. Biol. Chem., June 30, 2006; 281(26): 17968 - 17976. [Abstract] [Full Text] [PDF]

				K. E. Joung, K. N. Min, J. Y. An, D.-K. Kim, G. Kong, and Y. Y. Sheen Potent In vivo Anti-Breast Cancer Activity of IN-2001, a Novel Inhibitor of Histone Deacetylase, in MMTV/c-Neu Mice. Cancer Res., May 15, 2006; 66(10): 5394 - 5402. [Abstract] [Full Text] [PDF]

				A. Martirosyan, S. Leonard, X. Shi, B. Griffith, P. Gannett, and J. Strobl Actions of a Histone Deacetylase Inhibitor NSC3852 (5-Nitroso-8-quinolinol) Link Reactive Oxygen Species to Cell Differentiation and Apoptosis in MCF-7 Human Mammary Tumor Cells J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 546 - 552. [Abstract] [Full Text] [PDF]

				I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255. [Abstract] [Full Text] [PDF]

				R. R. Rosato, S. C. Maggio, J. A. Almenara, S. G. Payne, P. Atadja, S. Spiegel, P. Dent, and S. Grant The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide Mol. Pharmacol., January 1, 2006; 69(1): 216 - 225. [Abstract] [Full Text] [PDF]

				N. Gao, M. Rahmani, X. Shi, P. Dent, and S. Grant Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress Blood, January 1, 2006; 107(1): 241 - 249. [Abstract] [Full Text] [PDF]

				S. Skov, M. T. Pedersen, L. Andresen, P. Thor Straten, A. Woetmann, and N. Odum Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3-Dependent Expression of MHC Class I-Related Chain A and B Cancer Res., December 1, 2005; 65(23): 11136 - 11145. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785. [Abstract] [Full Text] [PDF]

				M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]

				W.-S. Xu, G. Perez, L. Ngo, C.-Y. Gui, and P. A. Marks Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects Cancer Res., September 1, 2005; 65(17): 7832 - 7839. [Abstract] [Full Text] [PDF]

				R. L. Bevins and S. G. Zimmer It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells Cancer Res., August 1, 2005; 65(15): 6957 - 6966. [Abstract] [Full Text] [PDF]

				J. C. Reed and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood, July 15, 2005; 106(2): 408 - 418. [Abstract] [Full Text] [PDF]

				D. Re, R. K. Thomas, K. Behringer, and V. Diehl From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential Blood, June 15, 2005; 105(12): 4553 - 4560. [Abstract] [Full Text] [PDF]

				K. A. Strait, C. T. Warnick, C. D. Ford, B. Dabbas, E. H. Hammond, and S. J. Ilstrup Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad Mol. Cancer Ther., April 1, 2005; 4(4): 603 - 611. [Abstract] [Full Text] [PDF]

				M. Rahmani, E. Reese, Y. Dai, C. Bauer, S. G. Payne, P. Dent, S. Spiegel, and S. Grant Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species Cancer Res., March 15, 2005; 65(6): 2422 - 2432. [Abstract] [Full Text] [PDF]

				H. Duan, C. A. Heckman, and L. M. Boxer Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas Mol. Cell. Biol., March 1, 2005; 25(5): 1608 - 1619. [Abstract] [Full Text] [PDF]

				M. G. Catalano, N. Fortunati, M. Pugliese, L. Costantino, R. Poli, O. Bosco, and G. Boccuzzi Valproic Acid Induces Apoptosis and Cell Cycle Arrest in Poorly Differentiated Thyroid Cancer Cells J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1383 - 1389. [Abstract] [Full Text] [PDF]

				R. Varshochi, F. Halim, A. Sunters, J. P. Alao, P. A. Madureira, S. M. Hart, S. Ali, D. M. Vigushin, R. C. Coombes, and E. W.-F. Lam ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor {alpha} from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line J. Biol. Chem., February 4, 2005; 280(5): 3185 - 3196. [Abstract] [Full Text] [PDF]

				J. Hu and N. H. Colburn Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-{kappa}B/p65 DNA Binding Mol. Cancer Res., February 1, 2005; 3(2): 100 - 109. [Abstract] [Full Text] [PDF]

				J. S. Ungerstedt, Y. Sowa, W.-S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P. A. Marks Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors PNAS, January 18, 2005; 102(3): 673 - 678. [Abstract] [Full Text] [PDF]

				J. B. Maxhimer, R. M. Reddy, J. Zuo, G. W. Cole Jr, D. S. Schrump, and D. M. Nguyen Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C) J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 53 - 63. [Abstract] [Full Text] [PDF]

				N. Gao, Y. Dai, M. Rahmani, P. Dent, and S. Grant Contribution of Disruption of the Nuclear Factor-{kappa}B Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol Mol. Pharmacol., October 1, 2004; 66(4): 956 - 963. [Abstract] [Full Text] [PDF]

				K. Camphausen, T. Scott, M. Sproull, and P. J. Tofilon Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation Clin. Cancer Res., September 15, 2004; 10(18): 6066 - 6071. [Abstract] [Full Text] [PDF]

				A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz, G. Holland, P. Boccuni, D. A. Scheinberg, A. Salama, K. Seeger, M. A. S. Moore, and S. D. Nimer Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins J. Leukoc. Biol., September 1, 2004; 76(3): 623 - 633. [Abstract] [Full Text] [PDF]

				X.-Y. Pei, Y. Dai, and S. Grant Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors Clin. Cancer Res., June 1, 2004; 10(11): 3839 - 3852. [Abstract] [Full Text] [PDF]

				M. Adachi, Y. Zhang, X. Zhao, T. Minami, R. Kawamura, Y. Hinoda, and K. Imai Synergistic Effect of Histone Deacetylase Inhibitors FK228 and m-Carboxycinnamic Acid Bis-Hydroxamide with Proteasome Inhibitors PSI and PS-341 against Gastrointestinal Adenocarcinoma Cells Clin. Cancer Res., June 1, 2004; 10(11): 3853 - 3862. [Abstract] [Full Text] [PDF]

				S. C. Maggio, R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells Cancer Res., April 1, 2004; 64(7): 2590 - 2600. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, C. Yu, and S. Grant Evidence of a Functional Role for p21WAF1/CIP1 Down-Regulation in Synergistic Antileukemic Interactions between the Histone Deacetylase Inhibitor Sodium Butyrate and Flavopiridol Mol. Pharmacol., March 1, 2004; 65(3): 571 - 581. [Abstract] [Full Text] [PDF]

				X. D. Zhang, S. K. Gillespie, and P. Hersey Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways Mol. Cancer Ther., February 1, 2004; 3(2): 187 - 197. [Abstract] [Full Text] [PDF]